Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
CPC211
- Development stage
- Preclinical
- Lead developer
- Alephoson
- Modality
- Small Molecules
- Administration
- Ophthalmic, Topical
01
Overview
CPC211 is a preclinical-stage small molecule therapeutic candidate being developed by Alephoson for the treatment of neovascular age-related macular degeneration (nAMD) and cataracts. The drug utilizes Alephoson's proprietary Cell-Penetrating Carrier (CPC) technology, which is designed to facilitate the non-invasive, topical delivery of therapeutic agents to both the anterior and posterior segments of the eye. By leveraging this platform, CPC211 aims to provide an alternative to traditional intravitreal injections for retinal diseases while also addressing lens-related pathologies. The specific molecular target and mechanism of action for CPC211 have not been publicly disclosed by the developer.
Beyond the preview
Go deeper on CPC211.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on CPC211.